Riskpilot← Back to searchSign inGet full accessLIFELINE PHARMA AS
ASActiveOrg 945808217Fridtjof Nansens Plass 9, 0160 OsloWholesale of other food · NACE 4638Est. 19873 employees
Revenue 2025
NOK 27,1M
+34% vs 2024
EBITDA margin
15.3%
+998% vs 2024
Equity ratio
11.7%
Financial strength
Net profit 2025
NOK 4,1M
+1137% vs 2024
| Revenue | NOK 27,1M | +34% |
| EBITDA | NOK 4,1M | +998% |
| Net profit | NOK 4,1M | +1137% |
| Total assets | NOK 23,2M | +196% |
| Equity | NOK 2,7M | +305% |
| Employees | 3 | — |
Legal name
LIFELINE PHARMA AS
Org number
945808217
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
21. oktober 1987
Share capital
NOK 100 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Address
Fridtjof Nansens Plass 9, 0160 Oslo
Email
contact@lifelinepharma.in
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 30 690 | 18 096 | 18 735 | 20 211 | 27 121 |
| Staff expenses | −2 611 | −2 112 | −2 258 | −1 499 | −942 |
| EBITDA | −2 287 | 1 059 | −673 | 377 | 4 141 |
| Depreciation & amort. | −7 | −7 | −7 | −3 | −0 |
| EBIT | −2 294 | 1 052 | −680 | 374 | 4 141 |
| Net financials | −175 | −258 | −715 | −47 | −87 |
| Profit before tax | −2 468 | 794 | −1 395 | 328 | 4 053 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 468 | 794 | −1 395 | 328 | 4 053 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 14 645 | 12 791 | 16 929 | 7 853 | 23 223 |
| Equity | −1 371 | −261 | −1 655 | −1 328 | 2 725 |
| Long-term debt | 1 772 | 4 185 | 12 932 | 6 433 | 11 180 |
| Short-term debt | 14 243 | 8 867 | 5 652 | 2 748 | 9 318 |
| Total debt | 16 016 | 13 052 | 18 584 | 9 181 | 20 498 |
EBITDA margin
15.3%
This company
15.8%
Market median
+3% vs market
20212025
Equity ratio
11.7%
This company
38.2%
Market median
-69% vs market
20212025
Return on equity
148.7%
This company
18.4%
Market median
+708% vs market
20212025
Net profit margin
14.9%
This company
8.1%
Market median
+84% vs market
20212025
Asset turnover
1.17×
This company
1.12×
Market median
+4% vs market
20212025
Debt / equity
7.52×
This company
0.62×
Market median
-1113% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YZ Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 30% | 30% | 2022 | |
| Company | 20% | 20% | 2023 | |
| Individual | 20% | 20% | 2022 | |
| Company | 20% | 20% | 2023 | |
| Individual | 10% | 10% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LIFELINE PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yunlin Zhan | Chief Executive Officer | 0 companies |
| Vegard Moltubakk | Chairman | 0 companies |